Sunac Therapeutics
Sunac Therapeutics is developing a first-in-class, single-dose regenerative gene therapy that targets cellular senescence—the root cause of osteoarthritis and degenerative disc disease. The treatment is delivered as a single intra-articular injection in the clinic and has been validated in both human arthritic tissue and animal models, with a pipeline expanding to treat all major osteoarthritis joints.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
Osteoarthritis and degenerative disc disease are chronic, progressive conditions for which current treatments only manage pain rather than restore tissue health. Patients face a lifetime of symptom suppression and eventual joint replacement, as no existing therapy addresses the underlying cellular deterioration driving the disease.
Solution
Sunac Therapeutics is developing a first-in-class, single-dose regenerative gene therapy that targets cellular senescence — the root cause of osteoarthritis and degenerative disc disease. The therapy restores the function of a single gene, which leads to epigenetic chromatin remodeling that returns arthritic cells to a healthy, functional state. These restored cells regain the ability to divide, reduce production of inflammatory cytokines, and promote tissue repair, effectively rebuilding the affected joint or disc using the patient's own cells. The treatment is delivered as a single intra-articular injection administered in the clinic, has been validated in both human arthritic tissue and animal models, and is positioned with a clear path to clinical readiness.
Target Audience
Primary customers are patients suffering from osteoarthritis and degenerative disc disease, along with the orthopedic clinicians and healthcare providers who treat these degenerative joint conditions.
Features
- Single-dose intra-articular injection designed to eliminate the need for repeat treatments
- Gene therapy mechanism targeting cellular senescence through epigenetic chromatin remodeling
- Restores function of a single gene to trigger broad cellular restoration and tissue repair
- Demonstrated ability to reverse senescence in damaged human arthritic cells, restoring division capacity and halting inflammatory cytokine production
- Validated in both human tissues and animal models with a clear path to clinical readiness
- Pipeline expanding beyond degenerative disc disease to target all major osteoarthritis joints